このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

マダガスカルの学童における腸内細菌叢と鉄状態へのコオロギおよびブラックソルジャーフライ幼虫強化クラッカーの影響

2026年11月6日 更新者:Cornell University

マダガスカルの学童における腸内細菌叢および鉄状態へのクリケットとブラックソルジャーフライ幼虫強化クラッカーの影響

The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar.

Specifically, in this RCT, the investigators will assess whether the insect-fortified crackers can improve the health status of Malagasy school children. The investigators' objectives are to: (1) Assess changes in gut microbiome composition that occur after 6 and 14 weeks of cracker consumption through 16S rRNA sequencing. (2) Assess changes in intestinal and systemic inflammation after 6 and 14 weeks of cracker consumption through quantification of fecal calprotectin, lactoferrin, myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT) and circulating pro-inflammatory cytokines. (3) Assess changes in iron status after 14 weeks of cracker consumption through quantification of hemoglobin (Hb), inflammation-adjusted serum ferritin, and soluble transferrin receptor (sTfR).

調査の概要

詳細な説明

Food insecurity, child malnutrition, and anemia remain significant public health problems globally, including in Madagascar where 40% of children under 5 years of age are chronically malnourished (stunted), 8% are wasted, and 46% are anemic (DHS, 2021). Interventions aimed at addressing this have often foundered on the fact that the foods that would address these nutrient deficiencies are physically unavailable, too expensive for poor households to purchase, or contribute to climate change or environmental degradation. Consequently, there is interest in the development of novel food products that could contribute to reducing malnutrition in all its forms, without the drawbacks of relying on existing food products. One possibility is to develop food products based on insects. Edible insects are low-cost, climate friendly, with nutritional profiles akin to meat. They contain high amounts of protein, iron, and zinc while also providing a novel source of prebiotic fiber. It is hypothesized that insect-based foods could improve children's health outcomes as measured by gut inflammation, anemia, and growth. The investigators and others have developed an insect-fortified cracker snack, suitable for the nutritional requirements of school-age children living in Southeast Madagascar. The investigators have already assessed the product's nutrient profile. They also have documented the safety tests done to date; these show that the snack is safe for human consumption. The test results have been submitted to the Malagasy regulatory authority for registering food and health products and the government has approved the insect powders as food for human consumption and issued "Certificates for Human Consumption". The investigators have also conducted an acceptability trial that showed that child participants like the organoleptic characteristics of the crackers and regularly consume the crackers in biologically meaningful quantities.

研究の種類

介入

入学 (実際)

482

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Vakinankaratra Region
      • Antsirabe、Vakinankaratra Region、マダガスカル
        • FSRP Sschools

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

9年~13年 (子)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion criteria for children

  • Child (male, female, intersex, non-binary), aged 9 to 13 years old who attends one of the selected schools
  • Caregiver or legal guardian is willing to provide informed consent
  • Child is willing to provide informed assent

Exclusion criteria for children

  • Child age is outside the preferred age range (9 to 13 years)
  • Not enrolled in the participating schools
  • Unable or unwilling to comply with the study requirements
  • Illness requiring medical treatment, malaria, severe anemia (hemoglobin (Hb) concentration below 8.0 g/dL as indicated by HemoCue 201+ system), severe acute malnutrition, fever, diarrhea, etc.
  • Covid-exposure or symptoms: loss of smell or taste
  • History of food allergies or adverse reactions to any edible insects
  • Chronic severe medical condition or congenital anomalies requiring frequent medical attention or interfering with dietary consumption
  • Caregiver does not give consent, or child does not assent

Inclusion criteria for parents • Willing to participate in completing surveys about demographics and household dynamics (assets, housing structure, etc.)

Exclusion criteria for parents

• Caregiver does not consent to participate

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment

Consumption of insect-fortified (crickets and black soldier fly larvae) crackers.

Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks.

他の名前:
  • 治療クラッカー
プラセボコンパレーター:Control

Consumption of rice and corn crackers

Children will receive a sachet containing 50g of insect crackers. 50 grams was chosen as the amount because the investigators know, from their earlier acceptability trial, that children are willing to consume this amount (in the acceptability trial, approximately 80% of children consumed 80% or more of the 50g of crackers that they were provided). Crackers will be provided Monday-Friday for approximately 14 weeks.

他の名前:
  • コントロール クラッカー

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Gut mircrobiome
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess gut microbiome composition at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through 16S rRNA sequencing and quantification of fecal biomarkers.

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Iron via soluble transferrin receptor
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through soluble transferrin receptor (mg/L).

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Intestinal inflammation via calprotectin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: calprotectin (µg/g).

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Intestinal inflammation via lactoferrin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lactoferrin (µg/g).

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Intestinal inflammation via lipocalin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: lipocalin (ng/g).

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Intestinal inflammation via anlpha-1 antitrypsin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: anlpha-1 antitrypsin (mg/g).

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Intestinal inflammation via myeloperoxidase
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess intestinal inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through the quantification of following fecal marker: myeloperoxidase (µg/g).

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Systemic inflammation via quantification of circulating cytokines
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will also assess systemic inflammation at baseline (0 weeks), midline (6 weeks), and endline (14 weeks) through quantification of circulating cytokines, including IL-1β, IL-2, IL-4, IL-6, IL-10, IL-22, TNF-α, IFN-γ, CCL2, all expressed as pg/mL.

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Iron via quantification of hemoglobin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through quantification of hemoglobin (g/dL).

From enrollment to the end of treatment after 14 weeks of cracker consumption.
Iron via inflammation adjusted ferritin
時間枠:From enrollment to the end of treatment after 14 weeks of cracker consumption.

The investigators will assess iron status at baseline (0 weeks) and endline (14 weeks) through inflammation adjusted ferritin (µg/L).

From enrollment to the end of treatment after 14 weeks of cracker consumption.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:John Hoddinott, DPhil、Cornell University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年2月1日

一次修了 (実際)

2026年6月30日

研究の完了 (実際)

2026年6月30日

試験登録日

最初に提出

2026年1月14日

QC基準を満たした最初の提出物

2026年2月23日

最初の投稿 (実際)

2026年2月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • IRB0149913

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD 共有時間枠

July 2026 to July 2027

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する